Wellington Management Group
SYRE icon

Wellington Management Group’s Spyre Therapeutics SYRE Stock Holding History

Wellington Management Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140M Sell
1,581,505
-243,306
-13% -$17.8M 0.02% 464
2026
Q1 		$92M Buy
1,824,811
+275,527
+18% +$10.4M 0.02% 565
2025
Q4 		$50.8M Sell
1,549,284
-91,028
-6% -$2.38M 0.01% 733
2025
Q3 		$27.5M Buy
1,640,312
+126,834
+8% +$2.07M ﹤0.01% 915
2025
Q2 		$22.7M Sell
1,513,478
-80,200
-5% -$1.19M ﹤0.01% 925
2025
Q1 		$25.7M Sell
1,593,678
-10,830
-0.7% -$225K ﹤0.01% 881
2024
Q4 		$37.4M Buy
1,604,508
+97,308
+6% +$2.85M 0.01% 789
2024
Q3 		$44.3M Buy
1,507,200
+711,254
+89% +$19.8M 0.01% 732
2024
Q2 		$18.7M Sell
795,946
-16,914
-2% -$571K ﹤0.01% 975
2024
Q1 		$30.8M Buy
812,860
+177,405
+28% +$5.14M 0.01% 846
2023
Q4 		$13.7M Buy
635,455
+335,526
+112% +$4.62M ﹤0.01% 1031
2023
Q3 		$3.67M Sell
299,929
-52,838
-15% -$698K ﹤0.01% 1357
2023
Q2 		$3.97M Buy
+352,767
New +$1.67M ﹤0.01% 1333

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Wellington Management Group's SYRE Position: Q2 2026 in Review

Wellington Management Group reduced its Spyre Therapeutics (SYRE) stake by 13% in Q2 2026, selling an estimated $17.8M and leaving 1,581,505 shares worth $140M. The position accounts for 0.02% of the portfolio, ranked #464.

Wellington Management Group first reported a position in SYRE in Q2 2023 and has held it in 13 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Wellington Management Group held 1,581,505 shares of Spyre Therapeutics worth $140M as of Q2 2026.
  • Wellington Management Group sold 243,306 Spyre Therapeutics shares in Q2 2026, an estimated $17.8M.
  • Spyre Therapeutics made up 0.02% of Wellington Management Group's portfolio in Q2 2026, its #464 holding.
  • Wellington Management Group first reported a position in Spyre Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.